Camp4 Registers 32.7M Resale Shares — 38.6% Overhang Now Tradable
CAMP has more than doubled off its 52-week low of $1.35 on elevated volume (2.3× avg).
Summary
Camp4's resale registration is effective, making 32.7 million shares from its recent private placement freely tradable — a 38.6% overhang that could pressure the stock.
Key Events · Financing and Capital Events · CAMP
-
Resale Registration Effective
The S-3 registration statement covering 32.7 million shares from the August 3 private placement is now effective, allowing selling stockholders to sell immediately.
-
38.6% Overhang
The resale shares represent approximately 38.6% of total outstanding common stock, creating a significant potential supply overhang.
-
No Proceeds to Company
Camp4 will not receive any proceeds from these resales; the $50.1 million was already raised in the private placement.
-
Profit Incentive for Sellers
Resale shares were acquired at $1.53-$1.65 per share, versus the August 11 closing price of $4.17, giving holders a strong incentive to sell.
Analysis · CAMP · Life Sciences
The registration statement covering 32.7 million shares from the August 3 private placement is now effective. Selling stockholders can immediately sell into the market, creating a substantial overhang of approximately 38.6% of outstanding shares. While the company received $50.1 million in gross proceeds, it will not receive any proceeds from these resales. The stock closed at $4.17 on August 11, and the resale shares were acquired at $1.53-$1.65, giving holders a significant profit incentive to sell.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $4.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $284.3M. The 52-week trading range was $1.35 to $7.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.